SLC3A2 and breast neoplasm: Since overexpression of SLC7A11 and SLC3A2 also reduced sensitivity of ER+ breast cancer cells to Fulvestrant treatment (Fig. 5H), we hypothesized that drug targeting SLC7A11 and SLC3A2 should have efficacy against endocrine-resistant breast tumors by inducing ferroptosis.